Who are SkQ1 Ophthalmic Solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MITT, Coenzyme Q10, Q10 Coenzyme, hypoglycemic Agents(metformin), Tafenoquine prophylaxis, Coenzyme Q10 (drug).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/skq1-ophthalmic-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

SkQ1 Ophthalmic Solution — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SkQ1 Ophthalmic Solution (SkQ1 Ophthalmic Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mitochondrially-targeted antioxidant. Area: Ophthalmology.

phase 3 Mitochondrially-targeted antioxidant Mitochondrial electron transport chain Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

SkQ1 Ophthalmic Solution (SkQ1 Ophthalmic Solution) — Mitotech, SA. SkQ1 Ophthalmic Solution is a mitochondrially-targeted antioxidant that aims to protect retinal cells from oxidative stress.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SkQ1 Ophthalmic Solution TARGET	SkQ1 Ophthalmic Solution	Mitotech, SA	phase 3	Mitochondrially-targeted antioxidant	Mitochondrial electron transport chain
MITT	MITT	AstraZeneca	marketed		Mitochondrial electron transport chain
Coenzyme Q10	Coenzyme Q10	Nanjing Medical University	marketed	Dietary supplement	Mitochondrial electron transport chain
Q10 Coenzyme	Q10 Coenzyme	Central Hospital, Nancy, France	marketed	Mitochondrial cofactor / Antioxidant	Mitochondrial electron transport chain (Complexes I, II, III)
hypoglycemic Agents(metformin)	hypoglycemic Agents(metformin)	First Affiliated Hospital of Wenzhou Medical University	marketed	Biguanide	AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain
Tafenoquine prophylaxis	Tafenoquine prophylaxis	Naval Medical Research Center	marketed	8-aminoquinoline antimalarial	Plasmodium mitochondrial electron transport chain
Coenzyme Q10 (drug)	Coenzyme Q10 (drug)	University of Shizuoka	marketed	Mitochondrial cofactor / Antioxidant	Mitochondrial electron transport chain (Complexes I-III, Complex IV)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mitochondrially-targeted antioxidant class)

Mitotech, SA · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SkQ1 Ophthalmic Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/skq1-ophthalmic-solution. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing